Table 3 Factors associated to the switch from standard to reduced dose and from reduced to standard dose in 31,171 s prescriptions.

From: Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation

 

Switch from standard to reduced dose OR (95% CI)

Switch from reduced to standard dose OR (95% CI)

Sex—Females vs Males

1.18 (1.11–1.24)

0.77 (0.71–0.84)

NOAC (ref Apixaban) Edoxaban vs Apixaban

1.1 (1.03–1.17)

0.54 (0.49–0.61)

NOAC (ref Apixaban) Dabigatran vs Apixaban

2.04 (1.96–2.13)

0.26 (0.24–0.27)

NOAC (ref Apixaban) Rivaroxaban vs Apixaban

1.16 (1.12–1.2)

0.6 (0.57–0.63)

 ≥ 65 and < 75 vs < 65 years

1.76 (1.6–1.93)

0.54 (0.47–0.61)

 ≥ 75 and < 85 vs < 65 years

4.95 (4.38–5.6)

0.18 (0.15–0.22)

 ≥ 85 vs < 65 years

11.82 (10.4–13.43)

0.07 (0.06–0.08)

CHA2DS2-VASc Score1 vs 0

1.03 (0.72–1.49)

0.79 (0.53–1.18)

CHA2DS2-VASc Score2 vs 0

1.02 (0.7–1.47)

0.69 (0.45–1.04)

CHA2DS2-VASc Score 3 vs 0

1.17 (0.79–1.72)

0.64 (0.41–0.99)

CHA2DS2-VASc Score 4 vs 0

1.3 (0.87–1.95)

0.6 (0.37–0.97)

CHA2DS2-VASc Score 5 vs 0

1.33 (0.86–2.03)

0.57 (0.33–0.98)

CHA2DS2-VASc Score 6 + vs 0

1.37 (0.86–2.18)

0.55 (0.3–1.02)

HAS-BLED Score1 vs 0

1.15 (0.96–1.37)

0.97 (0.75–1.26)

HAS-BLED Score 2 vs 0

1.2 (1–1.44)

0.84 (0.64–1.1)

HAS-BLED Score 3 vs 0

1.18 (0.97–1.44)

0.79 (0.59–1.05)

HAS-BLED Score 4 + vs 0

1.2 (0.96–1.49)

0.7 (0.51–0.97)

Diabetes history vs None

1.11 (1.05–1.18)

1.05 (0.96–1.15)

Hypertension history vs None

0.94 (0.88–1.01)

1.13 (1.01–1.26)

Stroke/TIA/Thromboembolism history vs None

0.98 (0.89–1.09)

1.07 (0.91–1.25)

Vascular disease history vs None

1.13 (1.07–1.19)

1.06 (0.97–1.15)

CHF history vs None

1.4 (1.32–1.48)

0.92 (0.85–1.01)

Alcohol use vs None

0.86 (0.8–0.93)

1.37 (1.22–1.53)

Liver disease vs None

1.06 (0.91–1.25)

0.92 (0.74–1.13)

Renal diseasea vs None

1.71 (1.55–1.89)

0.79 (0.71–0.87)

Prior major bleeding or predisposition to bleeding vs None

1.16 (1.09–1.23)

0.96 (0.89–1.05)

Labile INR vs No

1.03 (0.97–1.1)

1.01 (0.91–1.12)

Prior anticoagulant treatment (AVK) vs None

0.94 (0.9–0.99)

1.03 (0.95–1.11)

Medication usage predisposing to bleeding vs None

1.12 (1.06–1.18)

1.33 (1.23–1.44)

Prior NOAC treatment (switch) vs No

1.04 (0.97–1.11)

0.85 (0.78–0.93)

  1. Data are expressed as odds ratio and confidence intervals for the baseline characteristics and previous NOAC treatment.
  2. aRenal disease = renal transplantation or dialysis or plasma creatinin > 200 µmol/L.
Back to article page